Sabaa International Company for Pharmaceutical and Chemical Industry

CASE:SIPC Stock Report

Market Cap: ج.م335.0m

Sabaa International Company for Pharmaceutical and Chemical Industry Past Earnings Performance

Past criteria checks 0/6

Sabaa International Company for Pharmaceutical and Chemical Industry's earnings have been declining at an average annual rate of -57.5%, while the Pharmaceuticals industry saw earnings growing at 15.6% annually. Revenues have been declining at an average rate of 35.9% per year.

Key information

-57.5%

Earnings growth rate

-59.5%

EPS growth rate

Pharmaceuticals Industry Growth9.8%
Revenue growth rate-35.9%
Return on equity-8.3%
Net Margin-55.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Sabaa International Company for Pharmaceutical and Chemical Industry makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CASE:SIPC Revenue, expenses and earnings (EGP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2416-960
30 Jun 2413-760
31 Mar 2412-160
31 Dec 2313060
30 Sep 2313-460
30 Jun 2317-460
31 Mar 2319-160
31 Dec 2218060
30 Sep 2220270
30 Jun 2225570
31 Mar 2237480
31 Dec 21455100
30 Sep 216110120
30 Jun 216612140
31 Mar 216011180
31 Dec 207012200
30 Sep 207013180
30 Jun 20669190
31 Mar 207111170
31 Dec 19679180
30 Sep 19562180
30 Jun 19562180
31 Mar 19532180
31 Dec 18502160
30 Sep 185611140
30 Jun 188715110
31 Mar 18861780
31 Dec 17841770
30 Sep 17961170
30 Jun 1758770
31 Mar 1752570
31 Dec 1646560
30 Sep 1622260
30 Jun 1620260
31 Mar 1620360
31 Dec 1519260
30 Sep 1517250
30 Jun 1518350
31 Mar 1516260
31 Dec 1415250
30 Sep 1416260
30 Jun 1416360
31 Mar 1415350

Quality Earnings: SIPC is currently unprofitable.

Growing Profit Margin: SIPC is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SIPC is unprofitable, and losses have increased over the past 5 years at a rate of 57.5% per year.

Accelerating Growth: Unable to compare SIPC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SIPC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (37.9%).


Return on Equity

High ROE: SIPC has a negative Return on Equity (-8.25%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 04:46
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sabaa International Company for Pharmaceutical and Chemical Industry is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution